Advances in hypertension as reported at ACC 2025 include two new therapies that achieve significant blood pressure (BP) reduction, and a comparison of renal denervation methods for resistant BP.

TRYVIO (aprocitentan) in the US and JERAYGO in Europe present significant market potential as novel therapies for patients with hypertension inadequately controlled by existing treatments. TRYVIO ...

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

In pulmonary hypertension, a combination of metabolic and mechanical dysfunction leads to irreversible vascular damage.

Aprocitentan, on top of background therapy, showed clinically meaningful and durable blood pressure (BP) reduction and a decrease in proteinuria ...

But for some women, the postpartum journey can include unexpected health challenges—one of which is postpartum hypertension. While it may sound alarming, understanding this condition can go a ...

Mendelian randomization (MR) represents a valuable methodology to address the causal relationships between an exposure and an outcome. In MR studies, instrumental variables associated with the ...

The Jigawa State Government has announced plans to introduce free drugs for patients with diabetes, hypertension, and sickle cell disease across the state. The State Commissioner for Health ...

New research reveals that lower proportions of specific sleep stages are associated with reduced brain volume in regions vulnerable to the development of Alzheimer's disease over time. Results show ...

Image: Adobe Stock “We know aldosterone plays an outsize role in CVD and in hypertension in general,” Luke J. Laffin, MD, co-director of the Center for Blood Pressure Disorders at Cleveland ...